What is Zeroharm Sciences?
Zeroharm Sciences operates as a pioneering entity in the Indian nutraceutical market, distinguishing itself as the first brand to utilize advanced nanotechnology for the delivery of plant-based health supplements. By bridging the gap between traditional botanical wisdom and modern scientific rigor, the company offers a comprehensive suite of vitamins, minerals, and therapeutic products. Their core value proposition lies in the enhanced absorption rates of their nano-formulated products, which address critical consumer needs ranging from immunity support to metabolic health and weight management.
The company's market position is fortified by its commitment to sustainable wellness and clean-label manufacturing. By targeting the growing demographic of health-conscious consumers who prioritize natural, science-backed alternatives, Zeroharm Sciences has carved out a unique niche. Their operational strategy focuses on high-efficacy product development, ensuring that each supplement provides measurable health outcomes, thereby fostering long-term brand loyalty and market authority.
How much funding has Zeroharm Sciences raised?
Zeroharm Sciences has raised a total of $7.1M across 1 funding round:
Series A
$7.1M
Series A (2026): $7.1M with participation from Alkemi Venture Partners
Key Investors in Zeroharm Sciences
Alkemi Venture Partners
Alkemi Growth Capital LLP is an early-stage growth investor focused on supporting entrepreneurs in the Indian healthcare industry, dedicated to backing visionary founders who aim to elevate consumer well-being.
What's next for Zeroharm Sciences?
Looking ahead, the strategic deployment of the $7.1M will likely focus on scaling manufacturing capabilities and expanding the company's distribution footprint across both domestic and international markets. As the firm enters this new phase of enterprise-level growth, leadership is expected to prioritize R&D initiatives to further diversify their therapeutic portfolio. The integration of advanced data analytics to track consumer health outcomes will likely play a central role in their next growth cycle, enabling the company to refine its product offerings and maintain its competitive edge in the rapidly evolving health-tech ecosystem.
See full Zeroharm Sciences company page
